G-TPP targets mitochondrial-localized members of the HSP90 family including TNF receptor-associated protein-1 (TRAP1) and was developed to treat cancer cells where cytosolic HSP90s are abundant inside mitochondria. Here, TRAP1 is linked to cancer.